Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Bioventix (LSE:BVXP) remains a steady dividend payer in the FTSE AIM All Share Index ahead of full-year results

Bioventix develops and supplies high-affinity sheep monoclonal antibodies used in blood-testing diagnostics. Large diagnostics companies build these antibodies into their automated immunoassays, and Bioventix earns most of its income from royalties on the sale of those tests worldwide. Its long-established products include antibodies used …

Ankur Sharma | 13 October 2026

How Aptamer Group (LSE:APTA) is growing its pipeline as a FTSE AIM All Share Index biotech

Aptamer Group develops Optimer binders, a type of aptamer, which are short synthetic nucleic acid molecules designed to bind to specific targets. These binders can be used in diagnostics, therapeutics, laboratory tools and other applications as an alternative to antibodies. The company earns revenue …

Ankur Sharma | 13 October 2026

What Arecor Therapeutics' (LSE:AREC) £5m fundraise means for its insulin plans and FTSE AIM All Share Index profile

Arecor develops therapeutics for diabetes, obesity and other cardiometabolic diseases, using formulation technology to improve existing medicines. Its lead programmes are ultra-rapid-acting insulins. AT278 is an ultra-concentrated insulin at 500 units per millilitre, being co-developed with Sequel Med Tech towards Phase 2 readiness. AT290 …

Ankur Sharma | 13 October 2026

EDX Medical Group (LSE:EDX) Gains AIM Momentum as NHS Diagnostics Push and Commercial Deals Build

On 12 October 2026, EDX Medical Group PLC (LSE:EDX) is attracting attention as one of the more active healthcare names on AIM. Since moving to the market in May, the company has delivered a steady flow of operational news across cancer, infectious disease and …

Ankur Sharma | 13 October 2026

ImmuPharma (LSE:IMM) Under the AIM Spotlight as the 2026 P140 Licensing Deal Window Narrows

On 12 October 2026, ImmuPharma plc (LSE:IMM) is in focus as the final quarter of the year puts a spotlight on its stated goal of securing a P140 deal in 2026. The company has repeatedly said that partnering discussions are advancing and that P140 …

Ankur Sharma | 13 October 2026

IXICO Plc (LSE:IXI) Back on AIM Radar as Neuroimaging Specialist Closes FY26 With £8m Revenue Target in Sight

In early July, IXICO told the market it expected FY26 revenue of at least £8.0m, ahead of existing market expectations and about 22% above the previous year. That guidance came after a period of contract wins, extensions and a broader client base, and it …

Ankur Sharma | 13 October 2026

Coiled Therapeutics (LSE:COIL) Draws AIM Biotech Attention as First-in-Class TACC3 Cancer Drug Advances in Phase I

The shares were quoted around 7.90p in late September 2026, well below the 30p peak reached in November 2025. That gap, combined with an active Phase I trial, is keeping LSE:COIL on small-cap watchlists as investors wait for the next set of clinical milestones.

Ankur Sharma | 13 October 2026

Where Does Clinical Communications Pioneer Feedback plc (LSE:FDBK) Stand in the NHS?

Within the United Kingdom's National Health Service (NHS), clinical hospital staff and regional healthcare trusts confront an unprecedented challenge: millions of patients waiting on diagnostic backlogs for CT scans, MRIs, and outpatient specialist consultations. A major systemic driver of these delays is clinical workflow …

Ankur Sharma | 12 October 2026

What Could Drive US Commercial Expansion for Shield Therapeutics (LSE:STX)?

Iron deficiency and iron deficiency anemia represent the most prevalent nutritional disorder in the world, impacting over two billion people globally and millions of patients across the United States. It is a critical comorbidity in patients suffering from chronic kidney disease (CKD), inflammatory bowel …

Ankur Sharma | 12 October 2026

Why GSK (LSE:GSK) Says Its FTSE 100 Profit Growth Will Be Back-Loaded Into the Fourth Quarter

Ahead of its third-quarter results, GSK (LSE:GSK) has done something many large companies do but few investors read closely: it published an aide memoire. The note, released on 8 October 2026, is a reminder to analysts of the factors that will shape the quarter's …

Ankur Sharma | 12 October 2026
Support

Hi! How can we help you today?

Loading…